Aytu BioPharma (NASDAQ:AYTU) Stock Price Passes Above Fifty Day Moving Average – Here’s What Happened

Aytu BioPharma Inc. (NASDAQ:AYTU)’s stock price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $2.19 and traded as high as $2.33. Aytu BioPharma shares last traded at $2.30, with a volume of 49,804 shares traded.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on AYTU shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Monday, July 6th. Ascendiant Capital Markets upped their price objective on Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research report on Thursday, June 11th. Finally, Zacks Research downgraded Aytu BioPharma from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Aytu BioPharma has a consensus rating of “Hold” and a consensus price target of $10.75.

Aytu BioPharma Stock Performance

The business has a 50 day moving average price of $2.19 and a two-hundred day moving average price of $2.38. The stock has a market cap of $24.68 million, a P/E ratio of -0.50 and a beta of 0.25. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 0.27.

Aytu BioPharma (NASDAQ:AYTU) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.09). Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. The business had revenue of $12.41 million for the quarter, compared to the consensus estimate of $12.05 million. On average, sell-side analysts forecast that Aytu BioPharma Inc. will post -0.73 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aytu BioPharma

A number of large investors have recently added to or reduced their stakes in the company. Daytona Street Capital LLC purchased a new stake in shares of Aytu BioPharma during the 4th quarter valued at $26,000. Rothschild Wealth LLC purchased a new position in shares of Aytu BioPharma in the fourth quarter worth $52,000. Dimensional Fund Advisors LP acquired a new stake in shares of Aytu BioPharma during the third quarter worth $58,000. Bellevue Asset Management LLC acquired a new position in shares of Aytu BioPharma in the 4th quarter valued at $65,000. Finally, XTX Topco Ltd purchased a new position in Aytu BioPharma in the 4th quarter worth $67,000. 33.49% of the stock is currently owned by institutional investors.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.